SCHEMBL24253522

SCHEMBL24253522

CC(C)c1cc2nccnc2cc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
SLC6A2 P23975 2/20 0.42
HTR2B P41595 2/20 0.42
TRPA1 O75762 1/20 0.42
CHRM1 P11229 1/20 0.42
ADRA1A P35348 1/20 0.42
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
GABRA1 P14867 6/20 0.38
GABRB2 P47870 4/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 1/20 0.37
MAPK1 P28482 1/20 0.37
HSP90AA1 P07900 3/20 0.36
GABRB1 P18505 4/20 0.35
HSP90AB1 P08238 2/20 0.34
PKM P14618 1/20 0.34
HPGD P15428 2/20 0.33
FAAH O00519 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17049548 0.84 CA1 (0.35) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL21026904 0.77 ALDH1A1 (0.49) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL2961115 0.77 P2RX3 (0.49) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL21893416 0.76 ALDH1A1 (0.33) LMNAHPGDTSHRACHEKDM4E
SCHEMBL9879445 0.75 EGFR (0.39) PKMHPGDALDH1A1MAPTCASP1
SCHEMBL67859 0.75 LMNA (0.58) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL17132593 0.74 HTT (0.38) HPGDKDM4EALDH1A1TP53MAPT
SCHEMBL71456 0.73 LMNA (0.56) LMNASLC6A2HTR2BTRPA1CHRM1
SCHEMBL24248631 0.72 CA1 (0.33) CA1CA2GABRA1GABRB2GABRB1
SCHEMBL24253391 0.71 HSP90AB1 (0.40) LMNASLC6A2HTR2BTRPA1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 LMNA 301/4885SLC6A2 4676/4885HTR2B 4365/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885SLC6A2 4759/4885HTR2B 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.